Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure
Launched by CAREGGI HOSPITAL · Jul 25, 2019
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how extracorporeal blood purification therapies (EBPT) can help critically ill patients, particularly those dealing with severe conditions like acute kidney injury (AKI) or multiple organ failure. These therapies involve cleaning blood outside the body to improve health outcomes. The researchers want to see if certain groups of patients benefit more from these treatments, especially in terms of their chances of surviving after 28 days in the hospital.
To be eligible for this study, patients must be critically ill and receiving care in an intensive care unit (ICU). They should be undergoing specific EBPT methods to help with their kidney function or to reduce harmful substances in the blood. However, patients who are only receiving certain specialized treatments will not be included. If chosen to participate, patients and their families can expect close monitoring and to contribute to valuable research that may improve care for future patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • critically ill patients in the ICU
- * one of this EPB therapy:
- • CRRT/IHD/Hybrid therapies for support//replacement renal function
- • immunomodulation achieved by "high cut-off membranes", "endotoxins and/or cytokines adsorbent membranes" or by high-volume hemofiltration
- Exclusion Criteria:
- • patients treated only by Cytosorb® and/or Toraymyxin® therapies
About Careggi Hospital
Careggi Hospital, located in Florence, Italy, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and trials. As a prominent sponsor of clinical studies, Careggi Hospital integrates cutting-edge medical practices with rigorous scientific methodology to enhance patient care and outcomes. The institution is dedicated to fostering collaborations among healthcare professionals, researchers, and academic institutions, ensuring that its trials adhere to the highest ethical and regulatory standards. With a focus on patient safety and evidence-based medicine, Careggi Hospital plays a pivotal role in translating research findings into effective therapies and treatments for a diverse range of medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, , Italy
Brindisi, , Italy
Vicenza, , Italy
Torino, , Italy
San Donato Milanese, Milano, Italy
Florence, , Italy
Rozzano, Milano, Italy
Roma, , Italy
Florence, , Italy
Florence, Other, Italy
Empoli, Firenze, Italy
Lido Di Camaiore, Lucca, Italy
Monza, Monza Brianza, Italy
Pistoia, , Italy
Prato, , Italy
Reggio Calabria, , Italy
Roma, , Italy
Patients applied
Trial Officials
Gianluca Villa, MD
Principal Investigator
University of Florence, Florence, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials